Caner Type |
# of cases |
% |
Acute Lymphocytic Leukemia |
3 |
0.2% |
Acute Myeloid Leukemia |
3 |
0.2% |
Adrenal Carcinoma |
1 |
0.1% |
Anal Canal |
2 |
0.1% |
Appendix |
1 |
0.1% |
Benign Blood Disorders |
1 |
0.1% |
Benign Cases |
27 |
1.7% |
Bone Sarcoma |
8 |
0.5% |
Brain |
31 |
1.9% |
Breast |
380 |
23.5% |
Carcinoid Tumor |
1 |
0.1% |
Cervix |
7 |
0.4% |
Chronic Lymphocytic Leukemia |
7 |
0.4% |
Colon |
67 |
4.1% |
Double Primary |
16 |
1.0% |
Esophagus |
16 |
1.0% |
Exocrine Pancrease |
61 |
3.8% |
Extrahepatic Bile ducts |
8 |
0.5% |
Gall Bladder |
7 |
0.4% |
Germ Cell Tumors |
2 |
0.1% |
GIST |
6 |
0.4% |
Hodgikin Lymphoma |
15 |
0.9% |
Kidney |
19 |
1.2% |
Larynx |
3 |
0.2% |
Liver & Intrahepatic Bile Ducts |
91 |
5.6% |
M. Myeloma |
7 |
0.4% |
Melanoma |
10 |
0.6% |
Malignant Meningioma |
5 |
0.3% |
Mesothelioma |
13 |
0.8% |
MUO |
4 |
0.2% |
Multiple Primary Malignancies |
1 |
0.1% |
MUO to other organs |
19 |
1.2% |
MUO to respiratory and digestive organs |
15 |
0.9% |
Nasal Cavity & middle ear |
2 |
0.1% |
Nasopharynx |
5 |
0.3% |
NHL |
48 |
3.0% |
NSCLC |
64 |
4.0% |
Oral Cavity |
6 |
0.4% |
Ovary |
36 |
2.2% |
Parotid Gland |
2 |
0.1% |
Penis |
1 |
0.1% |
Peripheral Nerve & PNET |
3 |
0.2% |
Peritoneum |
5 |
0.3% |
1ry Skin Cancer |
1 |
0.1% |
Prostate |
73 |
4.5% |
Rectosigmoid Junction |
12 |
0.7% |
Rectum |
26 |
1.6% |
Salivary Glands |
2 |
0.1% |
Screening Breast |
40 |
2.5% |
Scortum |
1 |
0.1% |
Signet Ring Carcinoma |
2 |
0.1% |
Sinuses |
1 |
0.1% |
SCLC |
3 |
0.2% |
Small Intestine |
2 |
0.1% |
STS |
31 |
1.9% |
Spinal Cord & Cranial Nerves Tumors |
3 |
0.2% |
Squamous cell carcinoma |
8 |
0.5% |
Stomach |
16 |
1.0% |
Testicular Seminoma |
9 |
0.6% |
Thymic Tumors |
1 |
0.1% |
Thymoma |
3 |
0.2% |
Thyroid Gland |
33 |
2.0% |
Tongue |
6 |
0.4% |
Undiagnosed |
262 |
16.2% |
Urinary Bladder |
24 |
1.5% |
Urethra |
5 |
0.3% |
Uterus |
25 |
1.5% |
Vulva |
2 |
0.1% |
Total |
1,620 |
100.0% |